Impact of varicella vaccination in Argentina: Seroprevalence in children and adults in a pediatric hospital
Background: Varicella is the primary infection caused by varicella-zoster virus (VZV). In Argentina, the varicella vaccine was introduced in the National Immunization Programme in 2015 as a single dose scheduled at 15 months of age. Objectives: To estimate VZV seroprevalence in a healthy hospital ba...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-04-01
|
| Series: | Vaccine: X |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S259013622100053X |
| _version_ | 1811280098223980544 |
|---|---|
| author | Angela Gentile María del Valle Juarez María Florencia Lucion María Natalia Pejito Ana Clara Martínez Agostina Folino Mariana Viegas Norberto Giglio |
| author_facet | Angela Gentile María del Valle Juarez María Florencia Lucion María Natalia Pejito Ana Clara Martínez Agostina Folino Mariana Viegas Norberto Giglio |
| author_sort | Angela Gentile |
| collection | DOAJ |
| description | Background: Varicella is the primary infection caused by varicella-zoster virus (VZV). In Argentina, the varicella vaccine was introduced in the National Immunization Programme in 2015 as a single dose scheduled at 15 months of age. Objectives: To estimate VZV seroprevalence in a healthy hospital based population before and after vaccine introduction to the NIP. Material y Methods: Cross-sectional, observational, analytic study. Healthy subjects 1–40 years of age were included between June and December 2019 and tested for VZV-antibodies. Results were compared to data from a similar prevaccination study. Results: Out of 599 samples, 11 indeterminate results were excluded, 424 were positive; overall seroprevalence rate was 72.1% (95 %CI = 68,3–75,8%). No differences were observed between pre and post vaccination studies for overall prevalence or between age groups, except for vaccinated children aged 11–15 (p = 0,005). Rates increased in both periods in subjects aged 6 years or older. Primary vaccine failures were 21%; in subjects <5 years 83% seropositive cases had been vaccinated, in >5 year-olds >90% seropositive cases were associated with a history of infection (OR: 10,4; IC95%: 6,4–16,8; p < 0,001) or household contact (OR:4,8; IC95%: 3,1–7,6; p < 0,001). Vaccination protected against disease (OR: 0.25; 95 %CI: 0.09–0.68; p = 0.004). Conclusion: seroprevalence was high in all age groups except in unvaccinated 12 to 15-month infants. Seropositivity was due to vaccination in 15 months to 5 year-old children and to infection in older children. |
| first_indexed | 2024-04-13T01:07:18Z |
| format | Article |
| id | doaj.art-299709bb09f24a5caec4205df9b5ae46 |
| institution | Directory Open Access Journal |
| issn | 2590-1362 |
| language | English |
| last_indexed | 2024-04-13T01:07:18Z |
| publishDate | 2022-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Vaccine: X |
| spelling | doaj.art-299709bb09f24a5caec4205df9b5ae462022-12-22T03:09:17ZengElsevierVaccine: X2590-13622022-04-0110100136Impact of varicella vaccination in Argentina: Seroprevalence in children and adults in a pediatric hospitalAngela Gentile0María del Valle Juarez1María Florencia Lucion2María Natalia Pejito3Ana Clara Martínez4Agostina Folino5Mariana Viegas6Norberto Giglio7Epidemiology, Ricardo Gutiérrez Children’s Hospital, Buenos Aires, Argentina; Corresponding author at: Ricardo Gutiérrez Children’s Hospital, Gallo 1330 (1425), Buenos Aires City, Argentina.Epidemiology, Ricardo Gutiérrez Children’s Hospital, Buenos Aires, ArgentinaEpidemiology, Ricardo Gutiérrez Children’s Hospital, Buenos Aires, ArgentinaEpidemiology, Ricardo Gutiérrez Children’s Hospital, Buenos Aires, ArgentinaEpidemiology, Ricardo Gutiérrez Children’s Hospital, Buenos Aires, ArgentinaVirology, Ricardo Gutiérrez Children’s Hospital, Buenos Aires, ArgentinaVirology, Ricardo Gutiérrez Children’s Hospital, Buenos Aires, ArgentinaEpidemiology, Ricardo Gutiérrez Children’s Hospital, Buenos Aires, ArgentinaBackground: Varicella is the primary infection caused by varicella-zoster virus (VZV). In Argentina, the varicella vaccine was introduced in the National Immunization Programme in 2015 as a single dose scheduled at 15 months of age. Objectives: To estimate VZV seroprevalence in a healthy hospital based population before and after vaccine introduction to the NIP. Material y Methods: Cross-sectional, observational, analytic study. Healthy subjects 1–40 years of age were included between June and December 2019 and tested for VZV-antibodies. Results were compared to data from a similar prevaccination study. Results: Out of 599 samples, 11 indeterminate results were excluded, 424 were positive; overall seroprevalence rate was 72.1% (95 %CI = 68,3–75,8%). No differences were observed between pre and post vaccination studies for overall prevalence or between age groups, except for vaccinated children aged 11–15 (p = 0,005). Rates increased in both periods in subjects aged 6 years or older. Primary vaccine failures were 21%; in subjects <5 years 83% seropositive cases had been vaccinated, in >5 year-olds >90% seropositive cases were associated with a history of infection (OR: 10,4; IC95%: 6,4–16,8; p < 0,001) or household contact (OR:4,8; IC95%: 3,1–7,6; p < 0,001). Vaccination protected against disease (OR: 0.25; 95 %CI: 0.09–0.68; p = 0.004). Conclusion: seroprevalence was high in all age groups except in unvaccinated 12 to 15-month infants. Seropositivity was due to vaccination in 15 months to 5 year-old children and to infection in older children.http://www.sciencedirect.com/science/article/pii/S259013622100053XVaricellaPediatricsSeroprevalenceVaricella vaccine |
| spellingShingle | Angela Gentile María del Valle Juarez María Florencia Lucion María Natalia Pejito Ana Clara Martínez Agostina Folino Mariana Viegas Norberto Giglio Impact of varicella vaccination in Argentina: Seroprevalence in children and adults in a pediatric hospital Vaccine: X Varicella Pediatrics Seroprevalence Varicella vaccine |
| title | Impact of varicella vaccination in Argentina: Seroprevalence in children and adults in a pediatric hospital |
| title_full | Impact of varicella vaccination in Argentina: Seroprevalence in children and adults in a pediatric hospital |
| title_fullStr | Impact of varicella vaccination in Argentina: Seroprevalence in children and adults in a pediatric hospital |
| title_full_unstemmed | Impact of varicella vaccination in Argentina: Seroprevalence in children and adults in a pediatric hospital |
| title_short | Impact of varicella vaccination in Argentina: Seroprevalence in children and adults in a pediatric hospital |
| title_sort | impact of varicella vaccination in argentina seroprevalence in children and adults in a pediatric hospital |
| topic | Varicella Pediatrics Seroprevalence Varicella vaccine |
| url | http://www.sciencedirect.com/science/article/pii/S259013622100053X |
| work_keys_str_mv | AT angelagentile impactofvaricellavaccinationinargentinaseroprevalenceinchildrenandadultsinapediatrichospital AT mariadelvallejuarez impactofvaricellavaccinationinargentinaseroprevalenceinchildrenandadultsinapediatrichospital AT mariaflorencialucion impactofvaricellavaccinationinargentinaseroprevalenceinchildrenandadultsinapediatrichospital AT marianataliapejito impactofvaricellavaccinationinargentinaseroprevalenceinchildrenandadultsinapediatrichospital AT anaclaramartinez impactofvaricellavaccinationinargentinaseroprevalenceinchildrenandadultsinapediatrichospital AT agostinafolino impactofvaricellavaccinationinargentinaseroprevalenceinchildrenandadultsinapediatrichospital AT marianaviegas impactofvaricellavaccinationinargentinaseroprevalenceinchildrenandadultsinapediatrichospital AT norbertogiglio impactofvaricellavaccinationinargentinaseroprevalenceinchildrenandadultsinapediatrichospital |